Document is current
Any future updates will be listed below
-
Authors
Cetin, Irene
Devlieger, Roland
Isolauri, Erika
Obeid, Rima
Parisi, Francesca
Pilz, Stefan
van Rossem, Lenie
,
Steegers-Theunissen, Régine
-
Funding
Funding for this research was provided by:
Procter & Gamble (Not applicable)
- License Information
-
More Information
Article History
Received: 20 February 2024
Accepted: 26 December 2024
First Online: 20 January 2025
Declarations
:
: The study was reviewed by Pearl Institutional Review Board (2023-0047, ) and received a Category 2 exemption from full review, in accordance with the US Department of Health and Human Services and Code of Federal Regulations (CFR; 45 CFR 46.104(d)(2)). Participants gave informed consent to participate as part of the survey and could withdraw at any time.
: Not applicable.
: IC has received payments/honoraria unrelated to the present publication from Procter & Gamble (P&G), Bayer and Italfarmaco and has participated on a data safety monitoring board/advisory board for Italfarmaco. RD has received payments/honoraria unrelated to the present publication from P&G and Metagenics and participated on a data safety monitoring board/advisory board for Pfizer and Janssen Pharmaceuticals. RO and SP have received consulting fees and payments/honoraria unrelated to the present publication from P&G. All authors received payment for participation in a steering committee meeting related to the data presented in this manuscript.
